Plain-English translation of NCT05539729 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Researchers want to understand whether , an antibiotic, can help reduce brain inflammation in people with newly diagnosed multiple sclerosis. Your gut bacteria play a role in MS, and this medication may change those bacteria in ways that calm the immune system. This early-stage study will look at how the medication affects your gut microbiome, immune function, and brain lesions on MRI scans.
Scientists have discovered that the bacteria in your gut can influence brain inflammation and MS symptoms, but they don't yet know which specific bacteria matter most or how to target them. This trial investigates whether this medication can shift your gut bacteria in helpful ways—offering a potentially simple new approach to treating MS.
You likely qualify if…
You likely don't qualify if…
You will take either or a matching placebo pill four times daily by mouth. The study will monitor how the medication affects your gut bacteria through stool samples, check your immune function with blood tests, and track any changes in your brain lesions using MRI scans. As a Phase 1 trial with only 12 participants, this is a small, focused study designed to gather early safety and effectiveness information.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States